Pharma Major Lupin has launched its Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base) having received an approval from the United States Food and Drug Administration (USFDA) earlier.
Moxifloxacin Hydrochloride Ophthalmic solution USP, 0.5% (base), is an AT1 rated generic equivalent of Novartis Pharms Corp.’s Vigamox Ophthalmic solution. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the organisms. Vigamox Ophthalmic solution had US sales of $267.9 million as per IMS MAT March 2017.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
